The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.
Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
Emory and Eurofins, following their JV last year, plan to open several clinical genetics labs across the globe that draw on EGL's expertise.
Horizon Discovery will use its experience with gene editing, immunology, and oncology to develop immunotherapies based on Centauri's antibody conjugate technology.
The JV will be based in London with operations in Cambridge, Massachusetts and will develop new treatments for blood disorders, blindness, and congenital heart disease.
DiaGenomi offers a number of tests that combine DNA analysis with information about lifestyle and medical results to provide disease risk assessments.
A private financing fell short of its goal and the IDL joint venture has been unable to its obligations to GeneNews and Cobalt Healthcare, the owners of the JV.
In the second quarter, Quest reported revenues of $1.93 billion and estimated 2015 revenues will be between $7.49 billion and $7.57 billion.
The firms aim to establish the second largest lab services firm in the world to aid drugmakers with clinical trials.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.